AMLX (STOCKS)
Amylyx Pharmaceuticals, Inc. Common Stock
$16.433800
+0.073800 (+0.45%)
Prev close: $16.360000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joshua B. Cohen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,818.33M
- Employees
- 123
- P/E (TTM)
- -10.54
- P/B (TTM)
- 5.89
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.30 | $-0.37 | +0.0660 | +18.03% |
|
Sep 2025 (Q3)
|
$-0.37 | $-0.46 | +0.0889 | +19.37% |
|
Jun 2025 (Q2)
|
$-0.46 | $-0.45 | -0.0060 | -1.32% |
|
Mar 2025 (Q1)
|
$-0.42 | $-0.48 | +0.0645 | +13.31% |
Financial Statements
| Revenues | $0.00 |
| Cost Of Revenue | $0.00 |
| Costs And Expenses | $153.29M |
| Nonoperating Income/Loss | $8.60M |
| Selling, General, and Administrative Expenses | $62.89M |
| Research and Development | $90.40M |
| Operating Income/Loss | -$153.29M |
| Income/Loss From Continuing Operations After Tax | -$144.74M |
| Income/Loss From Continuing Operations Before Tax | -$144.69M |
| Income Tax Expense/Benefit | $46.00K |
| Income Tax Expense/Benefit, Current | $46.00K |
| Net Income/Loss | -$144.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$144.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$144.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.53 |
| Diluted Earnings Per Share | -$1.53 |
| Basic Average Shares | 94,565,567 |
| Diluted Average Shares | 94,565,567 |
| Assets | $332.65M |
| Current Assets | $323.67M |
| Noncurrent Assets | $8.97M |
| Fixed Assets | $310.00K |
| Other Non-current Assets | $8.66M |
| Liabilities | $27.39M |
| Current Liabilities | $22.69M |
| Accounts Payable | $3.52M |
| Wages | $10.06M |
| Other Current Liabilities | $9.11M |
| Noncurrent Liabilities | $4.70M |
| Equity | $305.26M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $305.26M |
| Liabilities And Equity | $332.65M |
| Net Cash Flow From Operating Activities | -$123.34M |
| Net Cash Flow From Operating Activities, Continuing | -$123.34M |
| Net Cash Flow From Investing Activities | $14.04M |
| Net Cash Flow From Investing Activities, Continuing | $14.04M |
| Net Cash Flow From Financing Activities | $257.03M |
| Net Cash Flow From Financing Activities, Continuing | $257.03M |
| Exchange Gains/Losses | $1.07M |
| Net Cash Flow | $148.80M |
| Net Cash Flow, Continuing | $147.73M |
| Comprehensive Income/Loss | -$144.24M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$144.24M |
| Other Comprehensive Income/Loss | $496.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $496.00K |